Position in XLO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$942,996
New position
Shares Held
112,128
first reported quarter
Ownership
1.94%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Caligan Partners LP holds $1,087,463,397 across 22 Biotechnology names. XLO ranks #22 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,461,924 | $162,785,237 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
1,652,808 | $160,735,578 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,060,719 | $119,748,381 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
1,393,027 | $81,004,520 | |
| 5 | MLYS |
Mineralys Therapeutics, Inc.
|
2,772,654 | $75,111,196 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,553,262 | $66,619,407 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
2,408,798 | $50,392,054 | |
| 8 | TYRA |
Tyra Biosciences, Inc.
|
1,276,968 | $48,907,874 |
All Filings in XLO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $942,996 | 112,128 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||